Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Compared to a limited cohort of 24 individuals with DS who had cytokine testing, the presence of any abnormality was significantly elevated in persons with DSRD (p = 0.02, 95%CI 1.23 to 17.74).Serum and neurodiagnostic studiesStudyDSRD results abnormal (n, %)DS results abnormal (n/N, %)p value95%CISerum analysis ANA9 (13%)21/422 (5%)0.011.20 to 5.26 Anti-DNAseB0 (0%)1/125 (1%)0.700.11 to 27.95 ASO (n = 58)0 (0%)6/204 (3%)0.470.05 to 3.87 B12 level7 (12%)64/1125 (6%)0.170.79 to 4.05 Celiac panel2 (3%)24/506 (5%)0.460.13 to 2.48 Complete metabolic profile5 (7%)88/1256 (7%)0.980.39 to 2.52 CRP (n = 62)0 (0%)15/433 (3%)0.360.05 to 2.98 dsDNA (n = 61)6 (10%)3/108 (3%)0.110.77 to 13.12 ESR (n = 66)0 (0%)16/612 (3%)0.530.07 to 3.96 Infectious screena12 (18%)n/an/an/a Neopterin (n = 42)0 (0%)0/12 (0%)n/an/a Methylmalonic acid (n = 61)9 (21%)14/203 (7%)0.150.79 to 4.67 Neurometabolic studies* (n = 32)1 (2%)3/188 (2%)0.900.09 to 8.49 Thyroid dysfunction (untreated)2 (4%)160/842 (19%)0.010.04 to 0.58 TPO antibodies (n = 43)25 (37%)110/478 (23%)0.021.06 to 2.16 Thyroglobulin antibodies (n = 42)20 (30%)107/465 (23%)0.370.80 to 1.82 Vitamin D (median, IQR)26.5 (15 to 34)39 (32 to 47)< 0.00110.57 to 16.9 Cytokine analysis (n = 50) TNF-alpha IL-2 sIL-2 receptor IL12 Interferon gamma IL-4 IL-5 IL-10 IL-13 IL-17 IL-1beta IL-6 IL-820 (40%)1 (5%)0 (0%)13 (62%)0 (0%)1 (5%)0 (0%)0 (0%)5 (24%)0 (0%)0 (0%)0 (0%)1 (5%)0 (0%)3/24 (13%)0 (0%)0 (0%)0 (0%)0 (0%)1 (4%)0 (0%)0 (0%)2 (8%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0.021.23 to 17.74Neurodiagnostic studies (DSRD only) EEG abnormalities19 (26%) Epileptiform discharges in frontal/temporal lobes11 (58%) Diffuse slowing (non-focal)6 (32%) Focal slowing2 (11%) Neuroimaging abnormalities16 (22%) Punctuate T2 hyperintensities (gray/white junction)13 (81%) Basal ganglia calcifications2 (13%) T2 signal prolongation in the temporal lobes1 (9%) Both T2 hyperintensities and calcifications1 (9%) Contrast enhancing lesions0 (0%) CSF abnormalities (n, %, median if abnormal)9 (17%) WBC5 (7%, 6) RBC0 Glucose0 Protein9 (13%, 68) Oligoclonal bands (n = 60)2 (3%, 2) IgG index (n = 60)7 (10%, 0.70) Mayo autoimmune encephalitis panel (n = 59)0 Neopterin (n = 43)6 (8%, 45) Any abnormal neurodiagnostic study?29 (40%) > 2 abnormal studies12 (17%)CI confidence interval*Neurometabolic studies included lactate, pyruvate, serum amino acids, urine organic acids, free and total carnitine, and acylcarnitine profilingNumber of patients with neurodiagnostic study abnormalities (n).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A retrospective, multi-center, case-control study was performed.

Source: Abstract.

Patients were required to have subacute onset and the presence of four of five symptom groups present (cognitive decline, expressive language, sleep derangement, loss of ability to perform activities of daily living, and/or a new movement disorder) and no other explanation for symptoms.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder

Case-control study · Journal of Neurodevelopmental Disorders · 2022

Original publication title

Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder

Jonathan D. Santoro; Rebecca Partridge; Runi Tanna; Dania Pagarkar; Mellad Khoshnood; Mustafa Rehmani; Ryan M. Kammeyer; Grace Y. Gombolay; Kristen Fisher; Allison Conravey; Jane El-Dahr; Alison L. Christy; Lina Patel; Melanie A. Manning; Heather Van Mater; Michael S. Rafii; Eileen A. Quinn

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study reports the novel presence of neurodiagnostic testing abnormalities in individuals with Down syndrome regression disorder, providing credence to this symptom cluster potentially being of neurologic and/or neuroimmunologic etiology.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Down syndrome regression disorder is a symptom cluster consisting of neuropsychiatric regression without cause. This study evaluated the incidence of neurodiagnostic abnormalities in individuals with Down syndrome regression disorder and determined if abnormalities are indicative of responses to therapeutic intervention.

Source: Background

Abstract: What methods does the paper describe?

A retrospective, multi-center, case-control study was performed. Patients were required to have subacute onset and the presence of four of five symptom groups present (cognitive decline, expressive language, sleep derangement, loss of ability to perform activities of daily living, and/or a new movement disorder) and no other explanation for symptoms.

Source: Methods

Abstract: Results

Individuals with Down syndrome regression disorder were comparable to a cohort of individuals with only Down syndrome although had higher rates of autoimmune disease (p = 0.02, 95%CI 1.04 to 1.75). Neurodiagnostic abnormalities were found on EEG (n = 19, 26%), neuroimaging (n = 16, 22%), and CSF (n = 9, 17%). Pleocytosis was appreciated in five cases, elevated total protein in nine, elevated IgG index in seven, and oligoclonal bands in two. Testing within 2 years of symptom onset was more likely to have neurodiagnostic abnormalities (p = 0.01, 95%CI 1.64 to 37.06).

In individuals with neurodiagnostic abnormalities, immunotherapy was nearly four times more likely to have a therapeutic effect than in those without neurodiagnostic abnormalities (OR 4.11, 95%CI 1.88 to 9.02). In those with normal neurodiagnostic studies (n = 43), IVIg was effective in 14 of 17 (82%) patients as well although other immunotherapies were uniformly ineffective.

Source: Results

Abstract: Conclusions

This study reports the novel presence of neurodiagnostic testing abnormalities in individuals with Down syndrome regression disorder, providing credence to this symptom cluster potentially being of neurologic and/or neuroimmunologic etiology.

Source: Conclusions
Authors’ abstract

Background

Down syndrome regression disorder is a symptom cluster consisting of neuropsychiatric regression without cause. This study evaluated the incidence of neurodiagnostic abnormalities in individuals with Down syndrome regression disorder and determined if abnormalities are indicative of responses to therapeutic intervention.

Methods

A retrospective, multi-center, case-control study was performed. Patients were required to have subacute onset and the presence of four of five symptom groups present (cognitive decline, expressive language, sleep derangement, loss of ability to perform activities of daily living, and/or a new movement disorder) and no other explanation for symptoms.

Results

Individuals with Down syndrome regression disorder were comparable to a cohort of individuals with only Down syndrome although had higher rates of autoimmune disease (p = 0.02, 95%CI 1.04 to 1.75). Neurodiagnostic abnormalities were found on EEG (n = 19, 26%), neuroimaging (n = 16, 22%), and CSF (n = 9, 17%). Pleocytosis was appreciated in five cases, elevated total protein in nine, elevated IgG index in seven, and oligoclonal bands in two. Testing within 2 years of symptom onset was more likely to have neurodiagnostic abnormalities (p = 0.01, 95%CI 1.64 to 37.06).

In individuals with neurodiagnostic abnormalities, immunotherapy was nearly four times more likely to have a therapeutic effect than in those without neurodiagnostic abnormalities (OR 4.11, 95%CI 1.88 to 9.02). In those with normal neurodiagnostic studies (n = 43), IVIg was effective in 14 of 17 (82%) patients as well although other immunotherapies were uniformly ineffective.

Conclusions

This study reports the novel presence of neurodiagnostic testing abnormalities in individuals with Down syndrome regression disorder, providing credence to this symptom cluster potentially being of neurologic and/or neuroimmunologic etiology.

Supplementary Information

The online version contains supplementary material available at 10.1186/s11689-022-09446-w.

Publication and source details

Original title: Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder

Jonathan D. Santoro; Rebecca Partridge; Runi Tanna; Dania Pagarkar; Mellad Khoshnood; Mustafa Rehmani; Ryan M. Kammeyer; Grace Y. Gombolay; Kristen Fisher; Allison Conravey; Jane El-Dahr; Alison L. Christy; Lina Patel; Melanie A. Manning; Heather Van Mater; Michael S. Rafii; Eileen A. Quinn

Journal of Neurodevelopmental Disorders · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T08:56:49.430679+00:00

DOI: 10.1186/s11689-022-09446-w · PMC9164321